Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ileocolic-released Conjugated Bile Acid in Obesity
NCT05314374Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- May 2023
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity (2 arms), sponsored by Mayo Clinic. Primary endpoints: Glucagon-Like Peptide-1 at 90 days and Peptide Tyrosine Tyrosine at 90 days. Started May 2023; status: completed.
02
Conditions
obesity
Beyond the preview
Go deeper on NCT05314374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05314374.